Literature DB >> 28814673

Human lung tumor FOXP3+ Tregs upregulate four "Treg-locking" transcription factors.

Tatiana Akimova1, Tianyi Zhang1, Dmitri Negorev1, Sunil Singhal2, Jason Stadanlick2, Abhishek Rao2, Michael Annunziata2, Matthew H Levine3, Ulf H Beier4, Joshua M Diamond5, Jason D Christie5,6, Steven M Albelda5, Evgeniy B Eruslanov2, Wayne W Hancock1.   

Abstract

Experimental data indicate that FOXP3+ Tregs can markedly curtail host antitumor immune responses, but the properties of human intratumoral Tregs are still largely unknown, in part due to significant methodologic problems. We studied the phenotypic, functional, epigenetic, and transcriptional features of Tregs in 92 patients with non-small-cell lung cancer, comparing the features of Tregs within tumors versus corresponding blood, lung, and lymph node samples. Intratumoral Treg numbers and suppressive function were significantly increased compared with all other sites but did not display a distinctive phenotype by flow cytometry. However, by undertaking simultaneous evaluation of mRNA and protein expression at the single-cell level, we demonstrated that tumor Tregs have a phenotype characterized by upregulated expression of FOXP3 mRNA and protein as well as significantly increased expression of EOS, IRF4, SATB1, and GATA1 transcription factor mRNAs. Expression of these "Treg-locking" transcription factors was positively correlated with levels of FOXP3 mRNA, with highest correlations for EOS and SATB1. EOS had an additional, FOXP3 mRNA-independent, positive correlation with FOXP3 protein in tumor Tregs. Our study identifies distinctive features of intratumoral Tregs and suggests that targeting Treg-locking transcription factors, especially EOS, may be of clinical importance for antitumor Treg-based therapy.

Entities:  

Keywords:  Immunology

Year:  2017        PMID: 28814673      PMCID: PMC5621877          DOI: 10.1172/jci.insight.94075

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  54 in total

1.  Measurement of Low-Abundance Intracellular mRNA Using Amplified FISH Staining and Image-Based Flow Cytometry.

Authors:  Andrea L Henning; Jill N Best Sampson; Brian Keith McFarlin
Journal:  Curr Protoc Cytom       Date:  2016-04-01

2.  Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC).

Authors:  Nasrollah Erfani; Shayesteh Mofakhami Mehrabadi; Mohammad Ali Ghayumi; Mohammad Reza Haghshenas; Zahra Mojtahedi; Abbas Ghaderi; Davar Amani
Journal:  Lung Cancer       Date:  2012-05-17       Impact factor: 5.705

Review 3.  Mechanisms of immune response regulation in lung cancer.

Authors:  Joanna Domagala-Kulawik; Iwona Osinska; Grazyna Hoser
Journal:  Transl Lung Cancer Res       Date:  2014-02

4.  Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients.

Authors:  Rebecca P Petersen; Michael J Campa; Justin Sperlazza; Debbi Conlon; Mary-Beth Joshi; David H Harpole; Edward F Patz
Journal:  Cancer       Date:  2006-12-15       Impact factor: 6.860

5.  Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation.

Authors:  Edward Y Woo; Heidi Yeh; Christina S Chu; Katia Schlienger; Richard G Carroll; James L Riley; Larry R Kaiser; Carl H June
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

6.  An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos.

Authors:  Madhav D Sharma; Lei Huang; Jeong-Hyeon Choi; Eun-Joon Lee; James M Wilson; Henrique Lemos; Fan Pan; Bruce R Blazar; Drew M Pardoll; Andrew L Mellor; Huidong Shi; David H Munn
Journal:  Immunity       Date:  2013-05-16       Impact factor: 31.745

Review 7.  COX-2 inhibition and lung cancer.

Authors:  Alan B Sandler; Steven M Dubinett
Journal:  Semin Oncol       Date:  2004-04       Impact factor: 4.929

8.  Standardization, Evaluation, and Area-Under-Curve Analysis of Human and Murine Treg Suppressive Function.

Authors:  Tatiana Akimova; Matthew H Levine; Ulf H Beier; Wayne W Hancock
Journal:  Methods Mol Biol       Date:  2016

Review 9.  IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  Trends Immunol       Date:  2016-01-31       Impact factor: 16.687

Review 10.  Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis.

Authors:  Erin A Marshall; Kevin W Ng; Sonia H Y Kung; Emma M Conway; Victor D Martinez; Elizabeth C Halvorsen; David A Rowbotham; Emily A Vucic; Adam W Plumb; Daiana D Becker-Santos; Katey S S Enfield; Jennifer Y Kennett; Kevin L Bennewith; William W Lockwood; Stephen Lam; John C English; Ninan Abraham; Wan L Lam
Journal:  Mol Cancer       Date:  2016-10-27       Impact factor: 27.401

View more
  29 in total

1.  Protein Kinase C Theta Modulates PCMT1 through hnRNPL to Regulate FOXP3 Stability in Regulatory T Cells.

Authors:  E Ilker Ozay; Sudarvili Shanthalingam; Joe A Torres; Barbara A Osborne; Gregory N Tew; Lisa M Minter
Journal:  Mol Ther       Date:  2020-06-15       Impact factor: 11.454

Review 2.  The role of FOXP3+ regulatory T cells in human autoimmune and inflammatory diseases.

Authors:  A Mohr; M Atif; R Balderas; G Gorochov; M Miyara
Journal:  Clin Exp Immunol       Date:  2019-03-24       Impact factor: 4.330

Review 3.  FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity.

Authors:  Theresa L Whiteside
Journal:  Expert Opin Ther Targets       Date:  2018-04-10       Impact factor: 6.902

Review 4.  SATB family chromatin organizers as master regulators of tumor progression.

Authors:  Rutika Naik; Sanjeev Galande
Journal:  Oncogene       Date:  2018-11-09       Impact factor: 9.867

Review 5.  Regulatory T cells in the treatment of disease.

Authors:  Amir Sharabi; Maria G Tsokos; Ying Ding; Thomas R Malek; David Klatzmann; George C Tsokos
Journal:  Nat Rev Drug Discov       Date:  2018-10-12       Impact factor: 84.694

6.  How little is known about the role of human FOXP3+ Tregs in tumors.

Authors:  Tatiana Akimova; Wayne W Hancock
Journal:  Expert Opin Ther Targets       Date:  2018-07-19       Impact factor: 6.902

Review 7.  Treg programming and therapeutic reprogramming in cancer.

Authors:  Mariela A Moreno Ayala; Zehui Li; Michel DuPage
Journal:  Immunology       Date:  2019-04-29       Impact factor: 7.397

Review 8.  Targeting the epigenetic regulation of antitumour immunity.

Authors:  Simon J Hogg; Paul A Beavis; Mark A Dawson; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2020-09-14       Impact factor: 84.694

9.  Human regulatory T cells (Treg) and their response to cancer.

Authors:  Theresa L Whiteside
Journal:  Expert Rev Precis Med Drug Dev       Date:  2019-07-15

10.  Obesity-related IL-18 Impairs T-Regulatory Cell Function and Promotes Lung Ischemia-Reperfusion Injury.

Authors:  Tatiana Akimova; Tianyi Zhang; Lanette M Christensen; Zhonglin Wang; Rongxiang Han; Dmitry Negorev; Arabinda Samanta; Isaac E Sasson; Trivikram Gaddapara; Jing Jiao; Liqing Wang; Tricia R Bhatti; Matthew H Levine; Joshua M Diamond; Ulf H Beier; Rebecca A Simmons; Edward Cantu; David S Wilkes; David J Lederer; Michaela Anderson; Jason D Christie; Wayne W Hancock
Journal:  Am J Respir Crit Care Med       Date:  2021-11-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.